Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM.
Desai MY, Wolski K, Owens A, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, Gong Z, Mudarris L, Lampl K, Sehnert AJ, Nissen SE; VALOR-HCM investigators. Desai MY, et al. Among authors: fermin d. Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072445. Online ahead of print. Circulation. 2024. PMID: 39556124
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.
Desai MY, Okushi Y, Wolski K, Geske JB, Owens A, Saberi S, Wang A, Cremer PC, Sherrid M, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Lampl KL, Sehnert AJ, Nissen SE, Popovic ZB; VALOR-HCM Investigators. Desai MY, et al. Among authors: fermin d. JACC Cardiovasc Imaging. 2024 Sep 2:S1936-878X(24)00345-0. doi: 10.1016/j.jcmg.2024.08.005. Online ahead of print. JACC Cardiovasc Imaging. 2024. PMID: 39254622 Free article.
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.
Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Zhong Y, Wyrwich KW, Lampl KL, Sehnert AJ, Nissen SE, Spertus JA; VALOR-HCM Investigators. Desai MY, et al. Among authors: fermin d. J Am Coll Cardiol. 2024 Sep 10;84(11):1041-1045. doi: 10.1016/j.jacc.2024.06.025. J Am Coll Cardiol. 2024. PMID: 39232631 Clinical Trial. No abstract available.
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD; SEQUOIA-HCM Investigators. Lee MMY, et al. JAMA Cardiol. 2024 Nov 1;9(11):990-1000. doi: 10.1001/jamacardio.2024.2781. JAMA Cardiol. 2024. PMID: 39230885 Free PMC article. Clinical Trial.
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
Desai MY, Okushi Y, Gaballa A, Wang Q, Geske JB, Owens AT, Saberi S, Wang A, Cremer PC, Sherrid M, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Lampl KL, Sehnert AJ, Nissen SE, Popovic ZB; VALOR-HCM Investigators. Desai MY, et al. Among authors: fermin d. Circ Cardiovasc Imaging. 2024 Sep;17(9):e017185. doi: 10.1161/CIRCIMAGING.124.017185. Epub 2024 Sep 2. Circ Cardiovasc Imaging. 2024. PMID: 39221824 Free PMC article. Clinical Trial.
Association of Genetically Predicted Skipping of COL4A4 Exon 27 with Hematuria and Albuminuria.
Lona-Durazo F, Omachi K, Fermin D, Eichinger F, Troost JP, Lin MH, Dinsmore IR, Mirshahi T, Chang AR, Miner JH, Paterson AD, Barua M, Gagliano Taliun SA. Lona-Durazo F, et al. Among authors: fermin d. J Am Soc Nephrol. 2024 Aug 27. doi: 10.1681/ASN.0000000000000480. Online ahead of print. J Am Soc Nephrol. 2024. PMID: 39190490 No abstract available.
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA‐HCM Investigators *. Coats CJ, et al. J Am Heart Assoc. 2024 Aug 6;13(15):e035993. doi: 10.1161/JAHA.124.035993. Epub 2024 Jul 26. J Am Heart Assoc. 2024. PMID: 39056349 Free article. Clinical Trial.
Correlating Molecular Precursor Interactions with Device Performance in Solution-Processed Cu2ZnSn(S,Se)4 Thin-Film Solar Cells.
Agbenyeke R, Sheppard A, Keynon J, Benhaddou N, Fleck N, Corsetti V, Alkhalifah MA, Tiwari D, Bowers JW, Fermin DJ. Agbenyeke R, et al. Among authors: fermin dj. ACS Appl Mater Interfaces. 2024 Jul 10;16(27):35315-35322. doi: 10.1021/acsami.4c05321. Epub 2024 Jun 27. ACS Appl Mater Interfaces. 2024. PMID: 38935097 Free PMC article.
134 results